Ketorolac Tromethamine
Tromethamine
Tolmetin
Mydriasis
Apazone
Ketorolac
Anti-Inflammatory Agents, Non-Steroidal
Ophthalmic Solutions
Administration, Topical
High-affinity binding of the AP-1 adaptor complex to trans-golgi network membranes devoid of mannose 6-phosphate receptors. (1/340)
The GTP-binding protein ADP-ribosylation factor (ARF) initiates clathrin-coat assembly at the trans-Goli network (TGN) by generating high-affinity membrane-binding sites for the AP-1 adaptor complex. Both transmembrane proteins, which are sorted into the assembling coated bud, and novel docking proteins have been suggested to be partners with GTP-bound ARF in generating the AP-1-docking sites. The best characterized, and probably the major transmembrane molecules sorted into the clathrin-coated vesicles that form on the TGN, are the mannose 6-phosphate receptors (MPRs). Here, we have examined the role of the MPRs in the AP-1 recruitment process by comparing fibroblasts derived from embryos of either normal or MPR-negative animals. Despite major alterations to the lysosome compartment in the MPR-deficient cells, the steady-state distribution of AP-1 at the TGN is comparable to that of normal cells. Golgi-enriched membranes prepared from the receptor-negative cells also display an apparently normal capacity to recruit AP-1 in vitro in the presence of ARF and either GTP or GTPgammaS. The AP-1 adaptor is recruited specifically onto the TGN and not onto the numerous abnormal membrane elements that accumulate within the MPR-negative fibroblasts. AP-1 bound to TGN membranes from either normal or MPR-negative fibroblasts is fully resistant to chemical extraction with 1 M Tris-HCl, pH 7, indicating that the adaptor binds to both membrane types with high affinity. The only difference we do note between the Golgi prepared from the MPR-deficient cells and the normal cells is that AP-1 recruited onto the receptor-lacking membranes in the presence of ARF1.GTP is consistently more resistant to extraction with Tris. Because sensitivity to Tris extraction correlates well with nucleotide hydrolysis, this finding might suggest a possible link between MPR sorting and ARF GAP regulation. We conclude that the MPRs are not essential determinants in the initial steps of AP-1 binding to the TGN but, instead, they may play a regulatory role in clathrin-coated vesicle formation by affecting ARF.GTP hydrolysis. (+info)A transfection compound series based on a versatile Tris linkage. (2/340)
The family of cationic lipid transfection reagents described here demonstrates a modular design that offers potential for the ready synthesis of a wide variety of molecular variants. The key feature of these new molecules is the use of Tris as a linker for joining the hydrophobic domain to a cationic head group. The molecular design offers the opportunity to conveniently synthesise compounds differing in charge, the number and nature of hydrophobic groups in the hydrophobic domain and the characteristics of the spacer between the cationic and hydrophobic moieties. We show that prototype reagents of this design can deliver reporter genes into cultured cells with efficiencies rivaling those of established cationic lipid transfection reagents. A feature of these reagents is that they are not dependent on formulation with a neutral lipid for activity. (+info)Inhibition of protein denaturation by fatty acids, bile salts and other natural substances: a new hypothesis for the mechanism of action of fish oil in rheumatic diseases. (3/340)
Natural hydrophobic substances like bile salts (cholate, deoxycholate, chenodeoxycholate, lithocholate and their conjugates with glycine and taurine), fatty acids (caprylic, capric, lauric, myristic, palmitic, stearic, oleic, linoleic, arachidonic, eicosapentaenoic and docosahexaenoic acid) were much more active (EC50 approximately 10(-4)-10(-5) M) than selected amino acids (EC50 > 10(-2) M) and inorganic salts (EC50 approximately 10(-1) M) in inhibiting heat-induced denaturation of human serum albumin in vitro. Fish oil, rich in n-3-polyunsaturated acids such as eicosapentaenoic acid and docosahexaenoic acid, administered p.o. (1 ml/kg) in the rat, protected ex vivo (after 2 hr) serum against heat-induced denaturation more than bendazac, a known antidenaturant drug. Thus, we speculated that the antidenaturant activity of fish oil may be partly (in addition to the known effect on endogenous eicosanoid composition) responsible for its beneficial effects in rheumatoid arthritis and other rheumatic conditions. In this connection, it is of note that the in vitro antidenaturant activity of fish oil fatty acids was higher than that of known antidenaturant drugs such as bendazac and bindarit and nonsteroidal anti-inflammatory drugs like phenylbutazone and indomethacin which could exert beneficial effects in chronic inflammatory conditions by stabilizing endogenous proteins. (+info)Hyaline membrane disease, alkali, and intraventricular haemorrhage. (4/340)
The relation between intraventricular haemorrhage (IVH) and hyaline membrane disease (HMD) was studied in singletons that came to necropsy at Hammersmith Hospital over the years 1966-73. The incidence of IVH in singleton live births was 3-22/1000 and of HMD 4-44/1000. Although the high figures were partily due to the large number of low birthweight infants born at this hospital, the incidence of IVH in babies weighing 1001-1500 g was three times as great as that reported in the 1658 British Perinatal Mortality Survey. Most IVH deaths were in babies with HMD, but the higher frequency of IVH was not associated with any prolongation of survival time of babies who died with HMD as compared with the 1958 survey. IVH was seen frequently at gestations of up to 36 weeks in babies with HMD but was rare above 30 weeks' gestation in babies without HMD. This indicated that factors associated with HMD must cause most cases of IVH seen at gestations above 30 weeks. Comparison of clinical details in infants with HMD who died with or without IVH (at gestations of 30-37 weeks) showed no significant differences between the groups other than a high incidence of fits and greater use of alkali therapy in the babies with IVH. During the 12 hours when most alkali therapy was given, babies dying with IVD received a mean total alkali dosage of 10-21 mmol/kg and those dying without IVH 6-34 mmol/kg (P less than 0-001). There was no difference in severity of hypoxia or of metabolic acidosis between the 2 groups. Babies who died with HMD and germinal layer haemorrhage (GLH) without IVH had received significantly more alkali than those who died with HMD alone, whereas survivors of severe respiratory distress syndrome had received lower alkali doses than other groups. It is suggested that the greatly increased death rate from IVH in babies with HMD indicates some alteration of management of HMD (since 1958) as a causative factor. Liberal use of hypertonic alkali solutions is the common factor which distinguishes babies dying with GLH and IVH from other groups of babies with HMD. Although the causal nature of this association remains unproved, it seems justifiable to lrge caution in alkali usage. (+info)Functional characterization of Escherichia coli inorganic pyrophosphatase in zwitterionic buffers. (5/340)
Catalysis by Escherichia coli inorganic pyrophosphatase (E-PPase) was found to be strongly modulated by Tris and similar aminoalcoholic buffers used in previous studies of this enzyme. By measuring ligand-binding and catalytic properties of E-PPase in zwitterionic buffers, we found that the previous data markedly underestimate Mg(2+)-binding affinity for two of the three sites present in E-PPase (3.5- to 16-fold) and the rate constant for substrate (dimagnesium pyrophosphate) binding to monomagnesium enzyme (20- to 40-fold). By contrast, Mg(2+)-binding and substrate conversion in the enzyme-substrate complex are unaffected by buffer. These data indicate that E-PPase requires in total only three Mg2+ ions per active site for best performance, rather than four, as previously believed. As measured by equilibrium dialysis, Mg2+ binds to 2.5 sites per monomer, supporting the notion that one of the tightly binding sites is located at the trimer-trimer interface. Mg2+ binding to the subunit interface site results in increased hexamer stability with only minor consequences for catalytic activity measured in the zwitterionic buffers, whereas Mg2+ binding to this site accelerates substrate binding up to 16-fold in the presence of Tris. Structural considerations favor the notion that the aminoalcohols bind to the E-PPase active site. (+info)Pharmacological characterization of the bradykinin B2 receptor: inter-species variability and dissociation between binding and functional responses. (6/340)
1. The present study addresses the differences in binding profiles and functional properties of the human and rat bradykinin (BK) B2 receptor using various kinin receptor peptide derivatives as well as the non-peptide receptor antagonists WIN 64338 (phosphonium, [[4-[[2-[[bis(cyclohexylamino)methylene]amino]-3-(2-naphtalenyl)1- oxopropyl]amino]-phenyl]-methyl]tributyl, chloride, monohydro-chloride), and FR173657 (E)-3-(6-acetamido-3-pyridyl)-N-[-N-[2,4-dichloro-3-[(2-methyl-8-quinoli nyl)oxymethyl]-phenyl]N-methylamino carbonyl methyl] acrylamide. 2. [3H]-BK bound with a similar affinity to membranes of Chinese hamster ovary cells (CHO-K1) expressing the cloned human (hB2-CHO) or rat (rB2-CHO) B2 receptor, human embryonic intestine cells (INT407) expressing the native B2 receptor, human umbilical vein (HUV) and rat uterus (RU). WIN 64338 and FR173657 bound with a 3.8-6.6 fold and 7.0-16.3 fold higher affinity the rat than the human B2 receptor, respectively. The affinity values of BK derivatives as well as non-peptide antagonists were reduced by 6-23 fold in physiological HBSS compared to low ionic strength TES binding buffer. 3. BK (0.01-3000 nM) increased inositol triphosphates (IP3) levels in hB2-CHO, rB2-CHO and INT407 cells. The B2 receptor antagonist, Hoe 140 (D-Arg0-[ Hyp3, Thi5, D-Tic7, Oic8]-BK) at 10(-7) M, significantly shifted to the right the IP3 response curves to BK giving apparent pKB values of 8.56, 9.79 and 8.84 for hB2-CHO, rB2-CHO and INT407 cells, respectively. 4. In human isolated umbilical vein, Hoe 140, D-Arg0-[Hyp3, D-Phe7, Leu8]-BK and NPC 567 had a lower potency in functional assays (pKB 8.18, 5.77 and 5.60, respectively) than expected from their affinity in binding studies (pKi 10.52, 8.64 and 8.27, respectively). 5. FR173657 behaved as a high affinity ligand with pKi values of 8.59 and 9.81 and potent competitive antagonist with pKB values of 7.80 and 8.17 in HUV and RU, respectively. FR173657 bound with a similar affinity the cloned and native bradykinin B2 receptor in human (pKi of 8.66 and 8.59, respectively) and in rat (pKi 9.67 and 9.81, respectively). 6. In conclusion, we suggest that the binding buffer composition has to be taken into account when screening new compounds and that inter-species differences should be considered when setting up animal models with the aim of developing bradykinin B2 receptor antagonists as therapeutic agents. (+info)A study of endonuclease III-sensitive sites in irradiated DNA: detection of alpha-particle-induced oxidative damage. (7/340)
An important difference between chemical agents that induce oxidative damage in DNA and ionizing radiation is that radiation-induced damage is clustered locally on the DNA. Both modelling and experimental studies have predicted the importance of clustering of lesions induced by ionizing radiation and its dependence on radiation quality. With increasing linear energy transfer, it is predicted that complex lesions will be formed within 1-20 bp regions of the DNA. As well as strand breaks, these sites may contain multiple damaged bases. We have compared the yields of single strand breaks (ssb) and double strand breaks (dsb) along with those produced by treatment of irradiated DNA with the enzyme endonuclease III, which recognizes a number of oxidized pyrimidines in DNA and converts them to strand breaks. Plasmid DNA was irradiated under two different scavenging conditions to test the involvement of OH* radicals with either 60Co gamma-rays or alpha-particles from a 238Pu source. Under low scavenging conditions (10 mM Tris) gamma-irradiation induced 7.1 x 10(-7) ssb Gy/bp, which increased 3.7-fold to 2.6 x 10(-6) ssb Gy/bp with endo III treatment. In contrast the yields of dsb increased by 4.2-fold from 1.5 x 10(-8) to 6.3 x 10(-8) dsb Gy/bp. This equates to an additional 2.5% of the endo III-sensitive sites being converted to dsb on enzyme treatment. For alpha-particles this increased to 9%. Given that endo III sensitive sites may only constitute approximately 40% of the base lesions induced in DNA, this suggests that up to 6% of the ssb measured in X- and 22% in alpha-particle-irradiated DNA could have damaged bases associated with them contributing to lesion complexity. (+info)Ooplasmic injections of rabbit round spermatid nuclei or intact round spermatids from fresh, cryopreserved and cryostored samples. (8/340)
We compared the outcome of ooplasmic round spermatid nuclear injections (ROSNI) versus intact round spermatid injections (ROSI). Rabbit round spermatid nuclei and intact round spermatids were recovered and injected into rabbit oocytes (groups A and B, respectively). Fertilization, cleavage and embryonic development rates were compared. In additional studies, five protocols for cryopreservation of round spermatids and two protocols for cryostorage of round spermatids were applied. The outcome of ROSNI techniques using frozen-thawed or cryostored-warmed round spermatids was evaluated. The cleavage rate and the overall morula plus blastocyst development rate were significantly larger in group A than group B. ROSNI procedures are superior to ROSI techniques in the rabbit. The largest fertilization, cleavage and embryonic development rates after ROSNI techniques using cryopreserved or cryostored round spermatids were demonstrated in groups of round spermatids in which a mixture of seminal plasma plus test yolk buffer was employed as an extender, and dimethyl sulphoxide plus a high concentration of glycerol served as cryoprotectants. It appears that the seminal plasma contains factors protecting round spermatids during cryopreservation or cryostorage, and/or the employment of two cryoprotectants has a beneficial role in the maintenance of round spermatid reproductive capacity. (+info)Ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in various clinical settings. It is a salt of ketorolac, which is a racemic mixture of R-(+)- and S-(-)-enantiomers.
Ketorolac tromethamine works by inhibiting the activity of cyclooxygenase (COX) enzymes, which are responsible for the production of prostaglandins, inflammatory mediators involved in pain and inflammation. By blocking the action of COX enzymes, ketorolac tromethamine reduces the production of prostaglandins, thereby alleviating pain and inflammation.
This medication is available as an injectable solution for intravenous (IV) or intramuscular (IM) administration, as well as in oral formulations. It is commonly used for short-term management of moderate to severe pain following surgery or trauma, as well as for the treatment of acute migraines and other painful conditions.
It's important to note that ketorolac tromethamine has a boxed warning from the U.S. Food and Drug Administration (FDA) due to its potential to increase the risk of serious gastrointestinal (GI) adverse events, such as bleeding, ulcers, and perforations, particularly when used for longer than recommended or at higher doses. Additionally, it may also increase the risk of cardiovascular events, renal toxicity, and anaphylaxis in some individuals. Therefore, its use should be closely monitored and managed by healthcare professionals to minimize potential risks.
Tromethamine is a chemical compound with the formula (CH2OH)3CNH2. It is also known as tris(hydroxymethyl)aminomethane or THAM. Tromethamine is a tertiary amine that acts as a buffer, maintaining a stable pH in various solutions.
In medical terms, tromethamine is used as a medication to correct acid-base imbalances in the body. It works by binding hydrogen ions and converting them into water and carbon dioxide, which can then be eliminated from the body. Tromethamine is often used in critically ill patients who have severe metabolic acidosis, a condition characterized by an excess of acid in the body that can lead to organ dysfunction and failure.
Tromethamine is available as a sterile solution for injection or as a powder to be reconstituted with sterile water for injection. It may also be used as an additive to intravenous fluids to help maintain a stable pH. Common side effects of tromethamine include local irritation at the injection site, nausea, vomiting, and headache.
Tolmetin is a non-steroidal anti-inflammatory drug (NSAID) that is used to relieve pain, inflammation, and fever. It works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation in the body. Tolmetin is available in immediate-release and sustained-release forms, and it is typically prescribed to treat conditions such as osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis.
The medical definition of Tolmetin can be found in various pharmaceutical and medical references, including the Merck Manual, the American Hospital Formulary Service (AHFS) Drug Information, and the National Library of Medicine's MedlinePlus. According to these sources, the chemical name for Tolmetin is (3R,5S)-3-(4-methylbenzoyl)-5-(3-methoxy-4-hydroxyphenyl)-1H-indole-2-one, and its molecular formula is C19H16NO3.
Tolmetin has a number of potential side effects, including stomach pain, nausea, vomiting, diarrhea, gas, dizziness, and headache. It can also increase the risk of serious gastrointestinal side effects, such as bleeding, ulcers, and perforations in the stomach or intestines, especially in people who are over the age of 65 or have a history of stomach ulcers or other gastrointestinal problems. Tolmetin can also increase the risk of heart attack, stroke, and other cardiovascular events, particularly in people who take it for a long time or at high doses.
Tolmetin is available only by prescription, and it should be taken exactly as directed by a healthcare provider. It is important to follow the instructions on the label carefully and to talk to a doctor or pharmacist if there are any questions about how to take Tolmetin or what the potential side effects may be.
Fosfomycin is an antibiotic that is primarily used to treat uncomplicated lower urinary tract infections. It works by inhibiting the bacterial enzyme responsible for the synthesis of the cell wall. The chemical name for fosfomycin is (E)-1,2-epoxypropylphosphonic acid.
Fosfomycin is available as an oral tablet and as a granule that can be dissolved in water for oral administration. It has a broad spectrum of activity against both gram-positive and gram-negative bacteria, including some strains that are resistant to other antibiotics.
Common side effects of fosfomycin include diarrhea, nausea, and headache. It is generally well tolerated and can be used in patients with impaired renal function. However, it should be avoided in people who have a history of allergic reactions to fosfomycin or any of its components.
It's important to note that the use of antibiotics like fosfomycin can lead to the development of bacterial resistance, so they should only be used when necessary and under the guidance of a healthcare professional.
I'm sorry for any confusion, but "Oxamic Acid" is not a recognized term in medical terminology or pharmacology. It might be a chemical compound that you're interested in, and its scientific definition is as follows:
Oxamic acid, systematically named as ethanedioloic acid or oxalic acid diethyl ester, is an organic compound with the formula (CH3CH2)2C(COOH)2. It is a colorless liquid that is used as a solvent and in the manufacture of other chemicals.
If you're looking for medical information or definitions related to a different term, please let me know and I would be happy to help!
Mydriasis is a medical term that refers to the dilation or enlargement of the pupil, which is the black circular opening in the center of the iris (the colored part) of the eye. The pupil normally adjusts its size in response to changes in light levels and emotional state. In mydriasis, the pupil becomes widely dilated and less responsive to light. This can occur naturally due to factors such as strong emotions, fear, or physical exertion, but it can also be caused by certain medications, eye drops, or medical conditions like brain injuries or neurological disorders. It is important to note that mydriasis can affect one or both eyes and may have different clinical significance depending on the context.
I'm sorry for any confusion, but "Apazone" is not a term recognized in medical terminology. It may be a proper name of a compound or medication from a specific company or context, but without more information, I cannot provide an accurate definition or meaning. In general, it's important to use precise and unambiguous language when discussing medical topics to ensure clear communication and understanding.
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that is used to treat moderate to severe pain. It works by reducing the levels of prostaglandins, chemicals in the body that cause inflammation and trigger pain signals in the brain. By blocking the production of prostaglandins, ketorolac helps to reduce pain, swelling, and fever.
Ketorolac is available in several forms, including tablets, injection solutions, and suppositories. It is typically used for short-term pain relief, as it can increase the risk of serious side effects such as stomach ulcers, bleeding, and kidney problems with long-term use.
Like other NSAIDs, ketorolac may also increase the risk of heart attack and stroke, especially in people who already have cardiovascular disease or risk factors for it. It should be used with caution and only under the supervision of a healthcare provider.
Non-steroidal anti-inflammatory agents (NSAIDs) are a class of medications that reduce pain, inflammation, and fever. They work by inhibiting the activity of cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins, chemicals that contribute to inflammation and cause blood vessels to dilate and become more permeable, leading to symptoms such as pain, redness, warmth, and swelling.
NSAIDs are commonly used to treat a variety of conditions, including arthritis, muscle strains and sprains, menstrual cramps, headaches, and fever. Some examples of NSAIDs include aspirin, ibuprofen, naproxen, and celecoxib.
While NSAIDs are generally safe and effective when used as directed, they can have side effects, particularly when taken in large doses or for long periods of time. Common side effects include stomach ulcers, gastrointestinal bleeding, and increased risk of heart attack and stroke. It is important to follow the recommended dosage and consult with a healthcare provider if you have any concerns about using NSAIDs.
Ophthalmic solutions are sterile, single-use or multi-dose preparations in a liquid form that are intended for topical administration to the eye. These solutions can contain various types of medications, such as antibiotics, anti-inflammatory agents, antihistamines, or lubricants, which are used to treat or prevent ocular diseases and conditions.
The pH and osmolarity of ophthalmic solutions are carefully controlled to match the physiological environment of the eye and minimize any potential discomfort or irritation. The solutions may be packaged in various forms, including drops, sprays, or irrigations, depending on the intended use and administration route.
It is important to follow the instructions for use provided by a healthcare professional when administering ophthalmic solutions, as improper use can lead to eye injury or reduced effectiveness of the medication.
Topical administration refers to a route of administering a medication or treatment directly to a specific area of the body, such as the skin, mucous membranes, or eyes. This method allows the drug to be applied directly to the site where it is needed, which can increase its effectiveness and reduce potential side effects compared to systemic administration (taking the medication by mouth or injecting it into a vein or muscle).
Topical medications come in various forms, including creams, ointments, gels, lotions, solutions, sprays, and patches. They may be used to treat localized conditions such as skin infections, rashes, inflammation, or pain, or to deliver medication to the eyes or mucous membranes for local or systemic effects.
When applying topical medications, it is important to follow the instructions carefully to ensure proper absorption and avoid irritation or other adverse reactions. This may include cleaning the area before application, covering the treated area with a dressing, or avoiding exposure to sunlight or water after application, depending on the specific medication and its intended use.
Urine is a physiological excretory product that is primarily composed of water, urea, and various ions (such as sodium, potassium, chloride, and others) that are the byproducts of protein metabolism. It also contains small amounts of other substances like uric acid, creatinine, ammonia, and various organic compounds. Urine is produced by the kidneys through a process called urination or micturition, where it is filtered from the blood and then stored in the bladder until it is excreted from the body through the urethra. The color, volume, and composition of urine can provide important diagnostic information about various medical conditions.
Fostemsavir
Fosfomycin
Analgesic
Prostaglandin F2alpha
Tris
Fosbretabulin
Ion channel hypothesis of Alzheimer's disease
Biochemistry of Alzheimer's disease
Zydus Lifesciences
Moderna COVID-19 vaccine
Carboprost
Nepafenac
List of MeSH codes (D03)
Krebs-Henseleit solution
List of MeSH codes (D02)
Postpartum bleeding
DailyMed - KETOROLAC TROMETHAMINE injection, solution
Ketorolac Tromethamine Tablets, USP 10mg
Acuvail (Ketorolac Tromethamine Ophthalmic Solution): Uses, Dosage, Side Effects, Interactions, Warning
Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due...
Generic Fosfomycin Tromethamine | Buy Monurol at Generic Pharmacy 1.866.995.7387
China Tromethamine, China J Acid, China 5-fluorocytidine, Products Catalog1
Sagent Pharmaceuticals, Inc. Recalls Ketorolac Tromethamine Injection, USP, 60mg/2mL
Sola Ketorolac Tromethamine Injection 30 mg/mL Vials 1 mL x 25/Tray (R - Mountainside Medical Equipment
tromethamine - 𓆰
Tromethamine
Tromethamine | CosDNA
Australian National Review - Tromethamine Is Being Secretly Added to Pfizer Shots
What is Ketorolac Tromethamine? | FoundHealth
Ketorolac Tromethamine | Generic Name | Pharmasia Limited
KETOROLAC TROMETHAMINE 10MG (TORADOL) TABS 100CT
Tromethamine-Tris-Excipient-BET-CP - Bio Spectra
carboprost tromethamine contraindications - MedInfo24.com | Medicines details
THAM (tromethamine injection) | Pfizer Medical Information - US
Dinoprost tromethamine Zhejiang Ausun Pharmaceutical Co., Ltd.
Ketorolac-tromethamine: View Uses, Side Effects & Medicines | Dawaai
tromethamine: Uses, Taking, Side Effects, Warnings - Medicine.com
THAM (tromethamine injection) Contraindications | Pfizer Medical Information - US
Buy R-Thiotic Acid Tromethamine on BIDCHEMZ | BIDCHEMZ India
Fosfomycin Tromethamine Coupons | Up to an 80% discount on prescription medication
Lipoic acid tromethamine salt-Product Center-Hangzhou Utanpharma Biology Co., LTD
A Multiinstitutional Evaluation of the Analgesic Efficacy and Safety of Ketorolac Tromethamine, Acetaminophen plus Codeine, and...
14358-90-8 R-alpha-Lipoic acid tromethamine salt - Watsonnoke Scientific ltd
Injection14
- The total combined duration of use of oral ketorolac tromethamine and ketorolac tromethamine injection should not exceed 5 days. (nih.gov)
- Doses of ketorolac tromethamine injection are not to exceed 60 mg (total dose per day) in these patients. (nih.gov)
- Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL). (fda.gov)
- This product was manufactured by Zydus (Cadila Healthcare Limited) and distributed by Sagent Pharmaceuticals, Inc. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP to the to the user level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products. (fda.gov)
- The company is recalling one lot of Ketorolac Tromethamine Injection, USP, 60mg/2mL because of a lack of sterility assurance. (biopharminternational.com)
- Sagent Pharmaceuticals, Inc. announced on April 30 that it was voluntarily recalling one lot of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) because of sterility assurance problems. (biopharminternational.com)
- Ketorolac Tromethamine Injection, USP, is a nonsteroidal anti-inflammatory drug (NSAID) used for the management of moderately severe acute pain that requires analgesia at the opioid level. (biopharminternational.com)
- Sola Ketorolac Tromethamine Injection 30 mg/mL Vials 1 mL is a highly effective and potent drug used for the management of moderate to severe pain. (mountainside-medical.com)
- The Ketorolac Tromethamine Injection 30 mg dose is particularly beneficial for patients suffering from post-operative pain, acute musculoskeletal conditions, or those in need of short-term pain relief. (mountainside-medical.com)
- The effectiveness and convenience of Sola Ketorolac Tromethamine Injection 30 mg/mL Vials 1 mL make it a preferred choice for both doctors and patients alike. (mountainside-medical.com)
- Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. (pfizermedicalinformation.com)
- Tham Solution (tromethamine injection) is administered by slow intravenous infusion, by addition to pump-oxygenator ACD blood or other priming. (pfizermedicalinformation.com)
- Tham Solution (tromethamine injection) is contraindicated in uremia and anuria. (pfizermedicalinformation.com)
- Tham Solution (tromethamine injection) is a sterile, non-pyrogenic 0.3 M solution of tromethamine, adjusted to a pH of approximately 8.6 with glacial acetic acid. (pfizermedicalinformation.com)
Ketorolac Tromethamine Tablets3
- Ketorolac tromethamine tablets, a non-steroidal anti-inflammatory drug (NSAID), are indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. (nih.gov)
- The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine should not exceed 5 days. (nih.gov)
- Ketorolac Tromethamine Tablets USP are a member of the pyrrolo-pyrrole group of non-steroidal anti-inflammatory drugs (NSAIDs). (nih.gov)
Nonsteroidal anti2
- Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level. (nih.gov)
- Acuvail (ketorolac tromethamine) Ophthalmic Solution is a nonsteroidal anti-inflammatory drug ( NSAID ) used to treat pain inflammation after cataract surgery or corneal refractive surgery, and also to relieve eye itching caused by seasonal allergies. (rxlist.com)
Carboprost tromethamine2
- Carboprost tromethamine Brand: Hemabate Class: Prostaglandins, Endocrine, Abortifacient Uses A medication called Hemabate (carboprost tromethamine) Sterile Solution contains prostaglandin, a hormone-like molecule found in the human body. (medinfo24.com)
- carboprost tromethamine increases effects of oxytocin by pharmacodynamic synergism. (medscape.com)
Fosfomycin7
- Our FREE fosfomycin tromethamine discount coupon helps you save money on the exact same fosfomycin tromethamine prescription you're already paying for. (rxgo.com)
- Print the coupon in seconds, then take it to your pharmacy the next time you get your fosfomycin tromethamine prescription filled. (rxgo.com)
- The fosfomycin tromethamine coupon is accepted at ALL CHAIN PHARMACIES such as CVS, Rite Aid, and Walgreens. (rxgo.com)
- Can I Use The fosfomycin tromethamine Coupon In Conjunction With My Insurance? (rxgo.com)
- Is this the same as a fosfomycin tromethamine manufacturer coupon? (rxgo.com)
- Administer orally as fosfomycin tromethamine. (drugs.com)
- In the United States, only an oral formulation containing fosfomycin tromethamine is approved for clinical use. (cdc.gov)
Tris4
- Tromethamine, sometimes called Tris, is like the behind-the-scenes ally that maintains stability in skin care products. (jessbeauty.com)
- Tromethamine (Tris), is commonly used as a buffer and excipient in biological applications downstream in the manufacture of drug products. (biospectra.us)
- The manufacturing of Tromethamine TRIS-3251 is performed at BioSpectra's Stroudsburg, PA facility and is conducted in a dedicated processing area using only dedicated equipment. (biospectra.us)
- BioSpectra certifies that all Tromethamine TRIS-3251 manufactured at BioSpectra and its raw materials are not derived from or come in contact with animal parts, products and/or byproducts. (biospectra.us)
Formulation2
- A suitable matrix system of ketorolac tromethamine (KTR) formulation has been developed with the aim of increasing the contact time, achieving controlled release, reducing the frequency of administration, improving patient compliance. (ugm.ac.id)
- In this current work pH triggered in situ ophthalmic gel of Moxifloxacin hydrochloride and Ketorolac tromethamine combination are prepared by using carbopol 934 as gelling agent and carboxy methyl tamarind kernel powder and Hydroxy propyl methyl cellulose K15M as viscosity enhancing agent and rate controlling polymer, Benzalkonium chloride was used as preservative in the above formulation. (journalcra.com)
Orally1
- Seventy‐five patients with moderate to severe cancer pain were randomly assigned in a double‐blind fashion to receive first‐dose ketorolac tromethamine 10 mg orally, acetaminophen 600 mg plus codeine 60 mg orally, or placebo, followed by subsequent doses of ketorolac or acetaminophen plus codeine four times daily for 7 days. (elsevierpure.com)
NSAID2
- Ketorolac tromethamine is CONTRAINDICATED in patients currently receiving aspirin or NSAIDs because of the cumulative risk of inducing serious NSAID-related side effects. (nih.gov)
- Ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. (nih.gov)
Allergic1
- Ketorolac tromethamine is CONTRAINDICATED in patients with previously demonstrated hypersensitivity to ketorolac tromethamine or allergic manifestations to aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). (nih.gov)
Medication1
- Our Acuvail (ketorolac tromethamine) Ophthalmic Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
Racemic1
- Ketorolac tromethamine, USP is a racemic mixture of [-]S and [+]R ketorolac tromethamine, USP. (nih.gov)
Gastrointestinal2
- Ketorolac tromethamine can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. (nih.gov)
- Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. (nih.gov)
Dose1
- Increasing the dose of ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will increase the risk of developing serious adverse events. (nih.gov)
Side Effects2
- What are the side effects of tromethamine that I need to call my doctor about immediately? (medicine.com)
- What are some other side effects of tromethamine? (medicine.com)
Acid3
- The chemical name for ketorolac tromethamine, USP is (±)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1). (nih.gov)
- Tromethamine is used to treat or prevent acid problems in the blood. (medicine.com)
- As one of the largest fine chemical developers globally, Watson solved the stability issue by bringing in two other derivates R(+)-Alpha Lipoic Acid Sodium CAS 176110-81-9 and R-alpha-Lipoic acid tromethamine salt CAS 14358-90-8, being one of the world's largest purveyor of commercially produced stabilized R-Lipoic Acid materials. (watsonnoke.com)
NSAIDs1
- ACUVAIL® (ketorolac tromethamine ophthalmic solution) 0.45% is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use. (rxlist.com)
Solution3
- 4.5 mg/mL ketorolac tromethamine solution (0.45%) in a single-use vial. (rxlist.com)
- When administered intravenously as a 0.3 M solution, tromethamine act as a proton acceptor and prevents or corrects acidosis by actively binding hydrogen ions (H + ). It binds not. (pfizermedicalinformation.com)
- In order to retain its effectiveness and purity for long, this 5 ML Moxifloxacin And Ketorolac Tromethamine Ophthalmic Solution is well packed using excellent grade packaging material. (grevispharma.in)
Ingredients1
- In addition to being an emulsifier, tromethamine can also help stabilize formulas, preventing ingredients from separating over time. (jessbeauty.com)
Intravenous1
- Oral ketorolac tromethamine is indicated only as continuation treatment following intravenous or intramuscular dosing of ketorolac tromethamine, if necessary. (nih.gov)
Clinical1
- The following adverse reactions have been identified during postmarketing use of ketorolac tromethamine ophthalmic solutions in clinical practice. (rxlist.com)
Pharmacist1
- If you need to store tromethamine at home, talk with your doctor, nurse, or pharmacist about how to store it. (medicine.com)
ADMINISTRATION3
- Ketorolac tromethamine is CONTRAINDICATED for intrathecal or epidural administration due to its alcohol content. (nih.gov)
- Too rapid administration and/or excessive amounts of tromethamine may cause alkalosis, hypoglycemia, overhydration or solute overload. (pfizermedicalinformation.com)
- Development and in-vitro evaluation of gelatin A microspheres of ketorolac tromethamine for intranasal administration. (ugm.ac.id)
Products2
- Tromethamine ensures that products have the right environment to deliver their benefits to your skin effectively. (jessbeauty.com)
- By ensuring products have the proper pH, tromethamine helps maintain healthy skin. (jessbeauty.com)
Medical1
- Outside of cosmetics, tromethamine is used in medical applications to reduce acidity. (cosdna.com)
Patients1
- Ketorolac tromethamine is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. (nih.gov)
White1
- As a raw material tromethamine appears as a white crystalline powder. (cosdna.com)
Pain1
- The use of ketorolac tromethamine in the management of post operative pain. (ugm.ac.id)